Currently, our Brinter® Bioprinter platform can be used in a variety of applications, such as a versatile tool for basic research in tissue engineering and regenerative medicine. 3D bioprinting solutions also offer a cost-effective approach to shorten and enhance the productivity of the drug discovery process. Bioprinted tissue models (e.g., liver) with multiple cell types and complex, native-like, physiological environment will eliminate the need for in vivo models during the drug discovery process. In addition, bioprinted liver models can also be used to assess hepatotoxicity and carcinogenicity of compounds, such as crop protection chemicals. Bioprinting can also be used to recapitulate the cancer microenvironment by precisely locating tumor cells and microcapillaries in a tumor tissue model to study cancer pathogenesis, growth, and metastasis.

The next new wave of personalized medicine will be customizable, patient-specific drugs. 3D bioprinting can tailor the geometry of a drug tablet to impact drug loading, release rate, and taste.

In the long run, our bioprinting technology will inspire solutions to address the shortage of organs for transplantation. Printing fully functional tissues and organs will become reality and enter clinical practice powered by advancements in biomaterials, bioprinting techniques and cell technology. Brinter is leading bioprinting companies in the quest for unlimited transplants.